Compile Data Set for Download or QSAR
Report error Found 46 Enz. Inhib. hit(s) with all data for entry = 11500
TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621073(US20230303562, Example 11 | Synthesis of 5-(3-(4-f...)
Affinity DataIC50: 0.5nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621068(US20230303562, Example 6)
Affinity DataIC50: 2.36nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621072(US20230303562, Example 10)
Affinity DataIC50: 4.82nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621067(US20230303562, Example 5)
Affinity DataIC50: 6.70nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621070(US20230303562, Example 8)
Affinity DataIC50: 8.27nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621074(US20230303562, Example 12)
Affinity DataIC50: 9.39nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621064(US20230303562, Example 3 | US20230303562, Example ...)
Affinity DataIC50: 9.83nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621066(US20230303562, Example 4)
Affinity DataIC50: 12nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621069(US20230303562, Example 7)
Affinity DataIC50: 27.2nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621071(US20230303562, Example 9)
Affinity DataIC50: 27.4nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621064(US20230303562, Example 3 | US20230303562, Example ...)
Affinity DataIC50: 43.8nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetActivin receptor type-1(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621055(US20230303562, Example 1 | 6-(1-(6-methylpyridin-2...)
Affinity DataIC50: 48.6nMAssay Description:(Promega), the inhibitory effect of the compounds of the present invention on the enzymatic activity of TGFβR1 was determined, and the steps wer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621073(US20230303562, Example 11 | Synthesis of 5-(3-(4-f...)
Affinity DataIC50: 593nMAssay Description:Experimental method: According to the instructions of ADP-Glo Kinase Detection Kit (Promega), the inhibitory effect of the compounds of the present i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621068(US20230303562, Example 6)
Affinity DataIC50: 690nMAssay Description:Experimental method: According to the instructions of ADP-Glo Kinase Detection Kit (Promega), the inhibitory effect of the compounds of the present i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621070(US20230303562, Example 8)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental method: According to the instructions of ADP-Glo Kinase Detection Kit (Promega), the inhibitory effect of the compounds of the present i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621074(US20230303562, Example 12)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental method: According to the instructions of ADP-Glo Kinase Detection Kit (Promega), the inhibitory effect of the compounds of the present i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621072(US20230303562, Example 10)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental method: According to the instructions of ADP-Glo Kinase Detection Kit (Promega), the inhibitory effect of the compounds of the present i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621064(US20230303562, Example 3 | US20230303562, Example ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental method: According to the instructions of ADP-Glo Kinase Detection Kit (Promega), the inhibitory effect of the compounds of the present i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621064(US20230303562, Example 3 | US20230303562, Example ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental method: According to the instructions of ADP-Glo Kinase Detection Kit (Promega), the inhibitory effect of the compounds of the present i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetTGF-beta receptor type-2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621055(US20230303562, Example 1 | 6-(1-(6-methylpyridin-2...)
Affinity DataIC50: 1.00E+3nMAssay Description:Experimental method: According to the instructions of ADP-Glo Kinase Detection Kit (Promega), the inhibitory effect of the compounds of the present i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621074(US20230303562, Example 12)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621074(US20230303562, Example 12)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621074(US20230303562, Example 12)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621073(US20230303562, Example 11 | Synthesis of 5-(3-(4-f...)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621073(US20230303562, Example 11 | Synthesis of 5-(3-(4-f...)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621073(US20230303562, Example 11 | Synthesis of 5-(3-(4-f...)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621072(US20230303562, Example 10)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621072(US20230303562, Example 10)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621072(US20230303562, Example 10)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621070(US20230303562, Example 8)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621070(US20230303562, Example 8)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621070(US20230303562, Example 8)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621068(US20230303562, Example 6)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621068(US20230303562, Example 6)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621068(US20230303562, Example 6)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 3A4(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621066(US20230303562, Example 4)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 2D6(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621066(US20230303562, Example 4)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetCytochrome P450 1A2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621066(US20230303562, Example 4)
Affinity DataIC50: 1.00E+4nMAssay Description:3.2. Inhibition of CYP2D6: Test group: The test compound of different concentration was added to the microplate, and Luciferin-ME EGE (3 μM), K3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621074(US20230303562, Example 12)
Affinity DataIC50: 1.00E+4nMAssay Description:1. Test System: Kit: Predictor hERG fluorescence polarization detection kit (ThermoFisher), the kit contained the following components: positive cont...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621073(US20230303562, Example 11 | Synthesis of 5-(3-(4-f...)
Affinity DataIC50: 1.00E+4nMAssay Description:1. Test System: Kit: Predictor hERG fluorescence polarization detection kit (ThermoFisher), the kit contained the following components: positive cont...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621072(US20230303562, Example 10)
Affinity DataIC50: 1.00E+4nMAssay Description:1. Test System: Kit: Predictor hERG fluorescence polarization detection kit (ThermoFisher), the kit contained the following components: positive cont...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621070(US20230303562, Example 8)
Affinity DataIC50: 1.00E+4nMAssay Description:1. Test System: Kit: Predictor hERG fluorescence polarization detection kit (ThermoFisher), the kit contained the following components: positive cont...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621069(US20230303562, Example 7)
Affinity DataIC50: 1.00E+4nMAssay Description:1. Test System: Kit: Predictor hERG fluorescence polarization detection kit (ThermoFisher), the kit contained the following components: positive cont...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621068(US20230303562, Example 6)
Affinity DataIC50: 1.00E+4nMAssay Description:1. Test System: Kit: Predictor hERG fluorescence polarization detection kit (ThermoFisher), the kit contained the following components: positive cont...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621066(US20230303562, Example 4)
Affinity DataIC50: 1.00E+4nMAssay Description:1. Test System: Kit: Predictor hERG fluorescence polarization detection kit (ThermoFisher), the kit contained the following components: positive cont...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Sichuan Kelun-Biotech Biopharmaceutical

US Patent
LigandPNGBDBM621055(US20230303562, Example 1 | 6-(1-(6-methylpyridin-2...)
Affinity DataIC50: 1.00E+4nMAssay Description:1. Test System: Kit: Predictor hERG fluorescence polarization detection kit (ThermoFisher), the kit contained the following components: positive cont...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
Go to US Patent